EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MicroRNA Let‐7b‐5p Targets IGF1R to Inhibit the Progression of Hepatocellular Carcinoma Through the AKT / mTOR Pathway

Jiaojiao Liang iD, Amin Li, Jun Chen, Niandie Cao, Tao Zhu, Ru Cai, Shuping Zhou, Yong Liang, Xiaolong Tang

Cancer Medicine · 2025

DOI: 10.1002/cam4.71000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jiaojiao Liang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, China. Hauptthemen laut MEDLINE: MicroRNAs, Carcinoma, Hepatocellular, Liver Neoplasms, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2023 Specialized Medical Cultivation Project of Anhui University Of Science & Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) remains a major global health burden, with microRNA Let‐7b‐5p (Let‐7b‐5p) emerging as a potential tumor suppressor. However, its precise role and molecular mechanisms in HCC progression remain unclear, necessitating further investigation.

Methods

We assessed Let‐7b‐5p expression in HCC versus normal hepatocytes via qRT‐PCR and employed functional assays (clone formation, EdU, scratch, Transwell, apoptosis) to examine its effects on proliferation, migration, and cell death. Mechanistic studies combined bioinformatics, Western blotting, and IHC to validate IGF1R as a target and assess AKT/mTOR pathway activity.

Results

Let‐7b‐5p was significantly downregulated in HCC cells, and its overexpression suppressed proliferation, migration, and enhanced apoptosis. Mechanistically, Let‐7b‐5p directly targeted IGF1R, leading to reduced phosphorylation of AKT/mTOR, indicating pathway inhibition.

Conclusions

Our findings establish Let‐7b‐5p as a critical regulator of HCC progression via IGF1R‐mediated AKT/mTOR suppression, offering a potential therapeutic strategy for HCC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsCarcinoma, HepatocellularLiver NeoplasmsTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktReceptor, IGF Type 1HumansSignal TransductionCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticCell Line, TumorApoptosisCell Movement

Stichwörter der Autor:innen

AKT/mTORhepatocellular carcinomainsulin‐like growth factor 1 receptormicroRNA let‐7b‐5p

Substanzen

MicroRNAsTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktmirnlet7 microRNA, humanIGF1R protein, humanMTOR protein, humanReceptor, IGF Type 1

Autor:innen und Institutionen

  • The First Affiliated Hospital of Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, China.
  • Medical College, Anhui University of Science & Technology, Huainan, China.
  • Huainan Maternity and Child Health Hospital, Huainan, China.
  • Central and Clinical Laboratory, The Affiliated Huaian Hospital of Xuzhou Medical University and Huaian Second Hospital, Huaian, China.

ORCID-Profile: Jiaojiao Liang

Förderung

  • 2023 Specialized Medical Cultivation Project of Anhui University Of Science & Technology

Zitieren

APA

Liang, J., Li, A., Chen, J., Cao, N., Zhu, T., Cai, R., Zhou, S., Liang, Y., & Tang, X. (2025). MicroRNA Let‐7b‐5p Targets IGF1R to Inhibit the Progression of Hepatocellular Carcinoma Through the AKT / mTOR Pathway. Cancer Medicine. https://doi.org/10.1002/cam4.71000

Vancouver

Liang J, Li A, Chen J, Cao N, Zhu T, Cai R, et al. MicroRNA Let‐7b‐5p Targets IGF1R to Inhibit the Progression of Hepatocellular Carcinoma Through the AKT / mTOR Pathway. Cancer Medicine. 2025. doi:10.1002/cam4.71000

BibTeX
@article{Liang2025,
  author = {Liang, Jiaojiao and Li, Amin and Chen, Jun and Cao, Niandie and Zhu, Tao and Cai, Ru and Zhou, Shuping and Liang, Yong and Tang, Xiaolong},
  title = {MicroRNA Let‐7b‐5p Targets IGF1R to Inhibit the Progression of Hepatocellular Carcinoma Through the AKT / mTOR Pathway},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71000}
}
Kostenlos starten →